The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio (QTTB) reported a Form 4 for a director reflecting a grant of stock options. The filing lists a Stock Option (Right to Buy) for 53,521 shares at an exercise price of $2.8 per share on 10/23/2025.
These options vest in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service on the vesting date. The option carries an expiration date of 10/22/2035 and is held directly. The grant price for the derivative security is shown as $0.00, consistent with option awards.
Q32 Bio Inc. (QTTB) reported an insider equity award on a Form 4. A director received a stock option grant covering 53,521 shares on 10/23/2025, with an exercise price of $2.80 per share and an expiration date of 10/22/2035. Ownership of the derivative security is listed as Direct.
The option vests in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the director’s continued service through that date. Following the reported transaction, the director beneficially owned 53,521 derivative securities.
Q32 Bio Inc. (QTTB) announced it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart for alopecia areata. The company disclosed the update via a press release titled “Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata,” furnished as Exhibit 99.1.
Jodie Pope Morrison, who serves as CEO and Director of Q32 Bio Inc. (QTTB), reported the automatic sale of 10,494 shares of common stock to satisfy tax withholding obligations from vested restricted stock units. The sales occurred on 08/26/2025 (deemed execution 08/27/2025) at a weighted average price reported as $1.801, with per-share prices ranging across two trading days from $1.73 to $1.96. Following the transactions, the reporting person beneficially owns 121,506 shares directly. The filing was signed by an attorney-in-fact on 08/28/2025.
Q32 Bio Inc. (QTTB) Chief Scientific Officer Shelia M. Violette reported the sale of 2,990 shares of common stock on 08/26/2025 with a weighted average price of $1.801 per share. The filing states the sales were automatic to satisfy tax withholding obligations related to the vesting of restricted stock units and were not at the reporting person’s discretion. After the transaction, Ms. Violette directly beneficially owns 58,384 shares and indirectly holds 36,277 shares through Violette Holdings LLC, of which she is a manager and disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. (QTTB) insider sale by CFO/President Lee Kalowski: The filing shows an automatic sale on 08/26/2025 of 4,240 shares of common stock to cover tax withholding from vested restricted stock units, reported at a weighted-average price of $1.801 per share. After the sale the reporting person beneficially owned 49,010 shares, held directly. The filing notes the shares were sold in multiple transactions over two consecutive trading days at per-share prices ranging $1.81–$1.96 and $1.73–$1.83. The form is signed by an attorney-in-fact on 08/28/2025.
Q32 Bio (NASDAQ:QTTB) announced the resignation of Chief Medical Officer Jason Campagna, M.D., Ph.D., effective July 9, 2025. The company has appointed Adrien Sipos, M.D., Ph.D. as Interim Chief Medical Officer, effective the same date. This Form 8-K filing discloses the leadership transition in the company's medical division.